Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

A new study examines how a diabetes drug may protect the kidneys from aging.

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), ...

In a new study published in Kidney International, researchers report that drugs known as SGLT2 inhibitors prevented ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...